PubMed:26498603 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":79},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":80,"end":90},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":91,"end":247},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":248,"end":256},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":257,"end":351},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":352,"end":488},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":489,"end":625},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":626,"end":634},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":635,"end":702},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":703,"end":817},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":818,"end":1026},"obj":"Sentence"},{"id":"TextSentencer_T12","span":{"begin":1027,"end":1254},"obj":"Sentence"},{"id":"TextSentencer_T13","span":{"begin":1255,"end":1266},"obj":"Sentence"},{"id":"TextSentencer_T14","span":{"begin":1267,"end":1452},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":79},"obj":"Sentence"},{"id":"T2","span":{"begin":80,"end":90},"obj":"Sentence"},{"id":"T3","span":{"begin":91,"end":247},"obj":"Sentence"},{"id":"T4","span":{"begin":248,"end":256},"obj":"Sentence"},{"id":"T5","span":{"begin":257,"end":351},"obj":"Sentence"},{"id":"T6","span":{"begin":352,"end":488},"obj":"Sentence"},{"id":"T7","span":{"begin":489,"end":625},"obj":"Sentence"},{"id":"T8","span":{"begin":626,"end":634},"obj":"Sentence"},{"id":"T9","span":{"begin":635,"end":702},"obj":"Sentence"},{"id":"T10","span":{"begin":703,"end":817},"obj":"Sentence"},{"id":"T11","span":{"begin":818,"end":1026},"obj":"Sentence"},{"id":"T12","span":{"begin":1027,"end":1254},"obj":"Sentence"},{"id":"T13","span":{"begin":1255,"end":1266},"obj":"Sentence"},{"id":"T14","span":{"begin":1267,"end":1452},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Short-course postpartum (6-h) magnesium sulfate therapy in severe preeclampsia.\nOBJECTIVE: To assess the efficacy of short-course postpartum (6-h) magnesium sulfate therapy versus 24-h conventional magnesium sulfate therapy in severe preeclampsia.\nMETHODS: Cases of severe preeclampsia were randomly allocated to group A (n = 76) and group B (n = 43). Group A and group B received magnesium sulfate loading dose (4 g) followed by infusion for 6 and 24 h postpartum (1 gm/h), respectively. Cases in both the groups were monitored closely after the initiation of therapy. t test and Chi-square test were used for data analysis.\nRESULTS: No occurrence of convulsions was noted in both group A and group B. The mean amount of magnesium sulfate used in the study group was 15.1 ± 5.4 g as against 42.3 ± 7.3 g in controls. The duration of Foley catheterization and monitoring was significantly less in group A (mean 11.3 ± 5.1 and 11.1 ± 4.9 h, respectively) as compared to group B (mean 38.3 ± 7.3 and 38.4 ± 7.2 h, respectively). The mean duration of hospital stay was 2.7 ± 0.7 days in cases delivered vaginally and 7.5 ± 1.6 days in those who underwent cesarean section in group A, while it was 4.04 ± 1.47 and 11.11 ± 3.14 days, respectively, in group B.\nCONCLUSION: Short-course, i.e., 6-h, postpartum magnesium sulfate therapy is as effective as conventional 24-h postpartum magnesium sulfate therapy in preventing convulsions in severe preeclampsia."}

{"project":"Preeclampsia","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":66,"end":78},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":234,"end":246},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":273,"end":285},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":1439,"end":1451},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Short-course postpartum (6-h) magnesium sulfate therapy in severe preeclampsia.\nOBJECTIVE: To assess the efficacy of short-course postpartum (6-h) magnesium sulfate therapy versus 24-h conventional magnesium sulfate therapy in severe preeclampsia.\nMETHODS: Cases of severe preeclampsia were randomly allocated to group A (n = 76) and group B (n = 43). Group A and group B received magnesium sulfate loading dose (4 g) followed by infusion for 6 and 24 h postpartum (1 gm/h), respectively. Cases in both the groups were monitored closely after the initiation of therapy. t test and Chi-square test were used for data analysis.\nRESULTS: No occurrence of convulsions was noted in both group A and group B. The mean amount of magnesium sulfate used in the study group was 15.1 ± 5.4 g as against 42.3 ± 7.3 g in controls. The duration of Foley catheterization and monitoring was significantly less in group A (mean 11.3 ± 5.1 and 11.1 ± 4.9 h, respectively) as compared to group B (mean 38.3 ± 7.3 and 38.4 ± 7.2 h, respectively). The mean duration of hospital stay was 2.7 ± 0.7 days in cases delivered vaginally and 7.5 ± 1.6 days in those who underwent cesarean section in group A, while it was 4.04 ± 1.47 and 11.11 ± 3.14 days, respectively, in group B.\nCONCLUSION: Short-course, i.e., 6-h, postpartum magnesium sulfate therapy is as effective as conventional 24-h postpartum magnesium sulfate therapy in preventing convulsions in severe preeclampsia."}

{"project":"Preeclampsia-compare","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":66,"end":78},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":234,"end":246},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":273,"end":285},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":1439,"end":1451},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Short-course postpartum (6-h) magnesium sulfate therapy in severe preeclampsia.\nOBJECTIVE: To assess the efficacy of short-course postpartum (6-h) magnesium sulfate therapy versus 24-h conventional magnesium sulfate therapy in severe preeclampsia.\nMETHODS: Cases of severe preeclampsia were randomly allocated to group A (n = 76) and group B (n = 43). Group A and group B received magnesium sulfate loading dose (4 g) followed by infusion for 6 and 24 h postpartum (1 gm/h), respectively. Cases in both the groups were monitored closely after the initiation of therapy. t test and Chi-square test were used for data analysis.\nRESULTS: No occurrence of convulsions was noted in both group A and group B. The mean amount of magnesium sulfate used in the study group was 15.1 ± 5.4 g as against 42.3 ± 7.3 g in controls. The duration of Foley catheterization and monitoring was significantly less in group A (mean 11.3 ± 5.1 and 11.1 ± 4.9 h, respectively) as compared to group B (mean 38.3 ± 7.3 and 38.4 ± 7.2 h, respectively). The mean duration of hospital stay was 2.7 ± 0.7 days in cases delivered vaginally and 7.5 ± 1.6 days in those who underwent cesarean section in group A, while it was 4.04 ± 1.47 and 11.11 ± 3.14 days, respectively, in group B.\nCONCLUSION: Short-course, i.e., 6-h, postpartum magnesium sulfate therapy is as effective as conventional 24-h postpartum magnesium sulfate therapy in preventing convulsions in severe preeclampsia."}